BPMC - Blueprint Medicines Corporation
| Previous Close | 78.48 |
| Open | 75.67 |
| Bid | 69.97 x 900 |
| Ask | 70.04 x 1000 |
| Day's Range | 69.77 - 76.83 |
| 52 Week Range | 44.58 - 102.98 |
| Volume | 882,598 |
| Avg. Volume | 468,295 |
| Market Cap | 3.5B |
| Beta (3Y Monthly) | 1.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.78 |
| Earnings Date | Feb 24, 2020 - Feb 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 106.31 |
- Zacks
Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses
Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.
- PR Newswire
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced initial data from the Phase 2 PIONEER clinical trial of avapritinib in patients with indolent systemic mastocytosis (SM). Initial data from the dose-finding Part 1 of the PIONEER trial showed rapid and robust reductions in serum tryptase, a well-established measure of mast cell burden, in patients treated with 25 mg, 50 mg or 100 mg of avapritinib once daily (QD). All dose levels of avapritinib tested were well-tolerated, and no patients discontinued treatment due to an adverse event (AE). The results will be presented today in a poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida.
- Insider Monkey
Hedge Funds Love Medicines Corporation (BPMC) Way More Than These Stocks
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Zacks
Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Being Overpaid?
Jeff Albers has been the CEO of Blueprint Medicines Corporation (NASDAQ:BPMC) since 2014. This analysis aims first to...
- Zacks
Blueprint Medicines (BPMC) Upgraded to Buy: What Does It Mean for the Stock?
Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- PR Newswire
Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference
CAMBRIDGE, Mass. , Nov. 14, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, ...
- Zacks
Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates
Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.
- PR Newswire
Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
-- Blueprint Medicines to Host Investor Event and Webcast on Sunday, December 8, 2019 -- CAMBRIDGE, Mass. , Nov. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy ...
- Zacks
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.87% and 148.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
CAMBRIDGE, Mass., Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its first R&D Day in New York City today. During the event, Blueprint Medicines will outline its vision to become a leading platform-enabled, fully-integrated, global precision therapy company. "As we prepare to launch our first medicine and submit multiple additional marketing applications next year, today we are unveiling our next wave of internally discovered research and clinical-stage precision therapies with the potential to deliver durable clinical benefits to additional patient populations," said Jeff Albers, Chief Executive Officer of Blueprint Medicines.
- GuruFocus.com
Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks
Health care-focused fund releases 3rd-quarter portfolio Continue reading...
- Insider Monkey
Were Hedge Funds Right About Selling Blueprint Medicines Corporation (BPMC)?
Is Blueprint Medicines Corporation (NASDAQ:BPMC) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
- PR Newswire
Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019
CAMBRIDGE, Mass. , Oct. 29, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced ...
- PR Newswire
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
CAMBRIDGE, Mass., Oct. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced an update regarding its New Drug Application (NDA) for avapritinib for the treatment of adults with PDGFRA Exon 18 mutant GIST, regardless of prior therapy, and fourth-line GIST.
- InvestorPlace
5 Biotech Stocks to Buy for a Strong Growth Prognosis
Biotech stocks have to be the ultimate risk and reward equities. No other sector comes close to the return potential of the sector. Just take a look at the gains for the SPDR S&P Biotech ETF (NYSE:XBI). The ETF and sector benchmark has managed to post average annual returns of nearly 19% over the last decade. That's pretty insane and underscores the kind of potential that biotech stocks can have.But they also come with a ton of risk to get that return. They don't call them lotto tickets for anything. Many biotech stocks are just one bad trial away from crashing, burning and causing plenty of heartache for their shareholders.However, there are ways to hedge your bets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAside from going into a broad ETF like the XBI, the key is making sure that investors focus on developmental pipelines, partnership and plenty of cash on their balance sheets. Having a drug actually in the marketing stages doesn't hurt either. It's here that investors can find success in the sector. * 7 Top-Notch REITs to Buy for Income With that in mind, here are five biotech stocks that have plenty of potential. Galapagos NV (GLPG)Source: Shutterstock A good way to spot top clinical-stage and early-entry biotech stocks is finding those firms with top-notch partners. And Galapagos NV (NASDAQ:GLPG) couldn't have picked a better partner than biotech royalty Gilead Sciences (NASDAQ:GILD). Earlier this year, GILD upped its partnership stake in GLPG via a nearly $4 billion payment as well as a $1.1 billion equity stake. All in all, Gilead will now own 22% of Galapagos.There's a good reason why GILD would want to pony up that kind of cash for the biotech firm. It needs to fill potential revenue holes in its aging pipeline and GLPG has the goods.Galapagos has one of the richest and largest development pipelines around. The drug company has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. This includes its potential blockbuster in Filgotinib. This was the first partnership with Gilead and after impressive phase-3 data for the rheumatoid arthritis drug, the duo submitted a marketing application with the FDA earlier this month. Meanwhile, successful initial idiopathic pulmonary fibrosis data, as well as beginning trials for new cystic fibrosis medicines, could all bare significant fruit for GLPG.That's an impressive amount of "shots on goal" for a clinical-stage biotech stock. The best part is, based on the rich deal, the speculation is that Galapagos wanted to stay independent rather than receive a full buyout from GILD. This means it can make the full use of that pipeline with future royalty and milestone payments. It also means investors in GLPG stock can as well. Blueprint Medicines (BPMC)Source: Shutterstock There are a few mega-trends in the world of biotech stocks. Gene therapy is a major one. Another is the concept of small-molecule drugs. Small-molecule drugs are generally more stable than their biologic counterparts and can more commonly be taken as pills as opposed to injections. Though some injected biologics can be taken outside of a healthcare setting (notably Abbvie's (NYSE:ABBV) Humira), many need to be administered by a doctor, nurse or other medical professional. This makes small-molecule drugs better for accessibility and ongoing treatments.This focus on small-molecule drugs makes Blueprint Medicines (NASDAQ:BPMC) a potential real winner among the biotech stocks.BPMC current roster of developmental drugs focuses on various cancers. And the beauty is that pill-delivery system. It really works. Avapritinib -- which treats systemic macrocytosis (SM) and gastrointestinal stromal tumors (GIST) -- managed to shrink these tumors in 86% of the patients treated. That's a high percentage for any study. The late trial success allowed Blueprint to submit a marketing application to the FDA for it. The firm has also seen great success targeting other cancers in several other early trials -- with the small -molecule delivery system leading the way. * 7 Top-Notch REITs to Buy for Income These successes allowed BPMC to plot its course of action for next year. That should include two marketed drugs, four in application stages and more than a dozen in trials and preclinical investigation. Given the wins already, there's no reason to think blueprint won't get there. Ligand Pharmaceuticals (LGND)Source: Shutterstock If one partner is good, then having over 100 is better. And this is the case for Ligand Pharmaceuticals (NASDAQ:LGND). LGND counts big shots like Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE) and generic drug specialist Teva (NASDAQ:TEVA) as some of partners/ licensees. The key is Ligand's business model.Ligand doesn't actually develop drugs itself. What it does is provide development platforms that help other biotech stocks and pharmaceutical companies create drugs more effectively. That huge difference has allowed Ligand to quietly become one of the sector's secret stars. Ligand gets upfront payments, development milestones and backend payments on sales after the drugs hit the marketing stages. So far, 17 drugs using Ligand's tech have been approved. But more are in the late stages of trials.Perhaps the best part is much of the development risk is pushed on the firms using LGND's tech. Ligand gets paid something either way.As a result, LGND is one of the few biotech stocks out there that is actually profitable. Moreover, the steady stream of royalties has allowed the firm to build up a massive war chest of just under $1.4 billion in cash on its balance sheet. While it's too early to talk about dividend potential, LGND could be on its way to initiating a payout in the future as more drugs hit pharmacy shelves using its technology.And yet, shares of LGND could be a massive bargain. After some hype has left the stock, investors can score shares about 30% below their year-aho levels. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Dominating a disease can mean some big-time revenues for biotech stocks. When it comes to cystic fibrosis, Vertex Pharmaceuticals (NASDAQ:VRTX) is pretty much the only game in town. It's three FDA-approved drugs -- Kalydeco, Orkambi, and Symdeko -- have a monopoly on the disease.]This massive foothold on cystic fibrosis treatments have made VRTX a cash cow for investors. Last year, Vertex managed to sell more than $3 billion worth of medicines to treat the disease. However, this year is looking to eclipse that rate. In 2019, VRTX expects to report product revenue of $3.5 billion to $3.7 billion. That puts it on track reap more than $5 billion in annual sales by 2024. Those robust sales have also helped balloon its cash balance to nearly $4 billion at the end of the quarter.And the future is robust for Vertex as well.The firm is working on a proved combination therapy of its three drugs to help boosts further, while Symdeko earlier this year received approval from the FDA to be used in children. The best news for VRTX could be a recent foray into gene editing that could treat cystic fibrosis completely. Partnering with CRISPR Therapeutics (NASDAQ:CRSP), Vertex recently started the first human trial using a CRISPR-based product. That drug -- CTX001 -- also received FDA fast track status and could be a huge revenue booster if approved. * 7 Top-Notch REITs to Buy for Income With its strong dominance, hefty cash flows and continued sales increases, VRTX has quickly become one of biotech's brightest stars. BioMarin Pharmaceuticals (BRMN)Source: Shutterstock Thanks to continued advances in science and technology, we're able to tackle more rare and orphan diseases. And thanks to their generally small patient population sizes and difficulty of treatment, drugs targeting this niche of the market often come with sky-high prices. For biotech stocks like BioMarin Pharmaceuticals (NASDAQ:BMRN) this is a revenue win.BRMN has made a name for itself as by only targeting rare diseases and has the most success in this area. The firm currently has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. BioMarin has continued to see rising sales and prescriptions for these medications. For example, during the last reported quarter, Vimizim and the PKU franchise managed to generate year-over-year revenue growth of 33% and 23%, respectively. All in all, total revenues for BRMN topped $460 million.And those revenues could keep soaring into the future.For one thing, rare disease medications often come with longer exclusivity rights. This gives BMRN a very long runway to ward off generic competition. Secondly, rare disease medications generally have no trouble getting covered by health insurers. This allows patients to actually get their hands on the high-priced meds in the first place.Adding in BioMarin's beefy pipeline and you have a recipe for success. Analysts expect the firm to finally start turning a profit by 2020 -- especially if its new hemophilia drug turns out to be a blockbuster.Disclosure: At the time of writing, Aaron Levitt was Long CRSP and the iShares NASDAQ Biotechnology ETF (IBB) -- which owns all the stocks on this list. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Cybersecurity Stocks to Keep Your Portfolio Safe * 7 Top-Notch REITs to Buy for Income * 5 Reasons Why I Still Believe in Hexo Stock The post 5 Biotech Stocks to Buy for a Strong Growth Prognosis appeared first on InvestorPlace.
- Simply Wall St.
Shareholders Are Thrilled That The Blueprint Medicines (NASDAQ:BPMC) Share Price Increased 153%
Blueprint Medicines Corporation (NASDAQ:BPMC) shareholders might be concerned after seeing the share price drop 24% in...
- Zacks
Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance
The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.
- Insider Monkey
This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks
DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […]
- Thomson Reuters StreetEvents
Edited Transcript of BPMC earnings conference call or presentation 1-Aug-19 12:30pm GMT
Q2 2019 Blueprint Medicines Corp Earnings Call
- Simply Wall St.
Does Blueprint Medicines Corporation (NASDAQ:BPMC) Have A Particularly Volatile Share Price?
If you own shares in Blueprint Medicines Corporation (NASDAQ:BPMC) then it's worth thinking about how it contributes...
- Zacks
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study
Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
- Motley Fool
4 Biotech Stocks With Big Catalysts in September
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
- Zacks
Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Blueprint Medicines to Present at Upcoming Investor Conferences in September
CAMBRIDGE, Mass. , Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, ...
